Denali therapeutics announces achievement of ripk1 milestone for phase 2 clinical trial initiation in multiple sclerosis by sanofi

South san francisco, calif., jan. 25, 2023 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that its partner sanofi has commenced dosing in a phase 2 study of sar443820 (dnl788) in individuals with multiple sclerosis. sar443820 is a central nervous system (cns)-penetrant investigational small molecule inhibitor of ripk1.
DNLI Ratings Summary
DNLI Quant Ranking